

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

## Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea ID1499

## Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Jazz Pharmaceuticals (solriamfetol)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• British Lung Foundation</li> <li>• British Snoring and Sleep Apnoea Association</li> <li>• Hope2Sleep</li> <li>• Muslim Council of Britain</li> <li>• OSA Partnership Group</li> <li>• Sleep Apnoea Trust</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• The Sleep Council</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association for Respiratory Technology &amp; Physiology</li> <li>• Association of Respiratory Nurse Specialists.</li> <li>• British Geriatrics Society</li> <li>• British Sleep Society</li> <li>• British Society of Dental Sleep Medicine</li> <li>• British Thoracic Society</li> <li>• National Heart and Lung Institute</li> <li>• Primary Care Respiratory Society UK</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine – Sleep medicine section</li> <li>• UK Clinical Pharmacy Association</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord-UK (methylphenidate)</li> <li>• Aurobindo Pharma - Milpharm (modafinil)</li> <li>• Flynn Pharma (dexamphetamine, methylphenidate)</li> <li>• Generics UK T/A Mylan (methylphenidate)</li> <li>• Janssen-Cilag (methylphenidate)</li> <li>• Lincoln Medical (pitolisant) hydrochloride</li> <li>• Martindale Pharma (dexamphetamine)</li> <li>• Novartis Pharmaceuticals UK (methylphenidate)</li> <li>• Sandoz (methylphenidate,)</li> </ul>

Consultees	Commentators (no right to submit or appeal)
<p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• NHS Nottingham West CCG</li> <li>• NHS Tameside &amp; Glossop CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Shire Pharmaceuticals Limited (methylphenidate)</li> <li>• Teva Pharma (modafinil)</li> <li>• UCB Pharma (sodium oxybate)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Brain Research UK</li> <li>• British Association for Lung Research</li> <li>• Cochrane Airways Group</li> <li>• Cochrane Common Mental Disorders Group</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEEES AND COMMENTATORS***

### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.